Market Intelligence, Clinical Progress, and High-Purity Reagents for Innate Immunity & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TLR5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TLR5 ECD-Fc / Mutant Protein (Human/Cyno/Mouse orthologs). High purity (>95%), Endotoxin <1EU/µg, HEK293 expressed. Sequence Verified. | View TLR5 Products |
| Gene Delivery | TLR5 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable reporter cell line generation. Native Glycosylation Preserved. | View TLR5 Products |
| Benchmark Ab | Anti-TLR5 Reference Antibody (Research Grade). Recombinant positive control for blocking and binding assay validation. | View TLR5 Products |
| Validator | TLR5 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View TLR5 Products |
| Related Target: TLR4 | TLR4 (Counter-screening). For selectivity assays against LPS receptor pathway. Synergistic innate immune signaling. | View TLR4 Products |
| Related Target: MYD88 | MYD88 (Adaptor Protein). Crucial downstream signaling node for pathway validation. | View MYD88 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Glycosylation | HEK293 Expressed (Native Glycosylation) ECD-Fc available with >95% purity |
| Complex Membrane Protein Expression | Premade Lentivirus for stable cell line generation to preserve conformation |
| Species-specific flagellin recognition (Human vs. Cyno vs. Mouse) | Ortholog Panel: Human, Cyno, and Mouse TLR5 ECD proteins with >95% purity for cross-reactivity screening |
| TLR selectivity screening (avoid TLR4/TLR2 activation) | Homologous TLR Panel: TLR2, TLR4, TLR9 proteins available for off-target profiling |
| Functional agonist/antagonist validation | Full-length TLR5 Lentivirus for stable NF-κB reporter cell line construction |
| Specificity confirmation / False Positives | Sequence-verified TLR5 siRNA included for genetic knockdown controls |
| Lack of Positive Controls | Clinical Benchmark Antibodies included |
Live TLR5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TLR5 therapeutics is intensifying, with major players exploring both agonists for oncology and radiation protection, and antagonists for inflammatory diseases. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal immunomodulation with reduced systemic toxicity through precise combination regimens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Protein Agonist | Cleveland BioLabs | Radiation Syndrome, Oncology | Cell-based Activation Assay (Need Lentivirus for Cell Line) |
| Monoclonal Antibody | Various Biopharma | Inflammatory Bowel Disease | Binding / Blocking Assay (Need high-purity ECD-Fc) |
| Gene Therapy | Panacela Labs | Solid Tumors | Expression Validation (Need sequence verified standards) |